- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT03200366
Comparing Interventions to Increase Colorectal Cancer Screening
Comparing Interventions to Increase Colorectal Cancer Screening in Low-Income and Minority Patients
The purpose of this study is to test different approaches to help people understand the purpose of colorectal cancer (CRC) screening, two screening test options available, and the barriers to screening so they can make informed decisions about CRC screening. Participants will be randomly assigned to one of three groups: (1) one group will receive a tailored digital video disc (DVD) in the mail; (2) another group will receive the mailed DVD plus telephone calls from a patient navigator; and (3) the third group will receive the care normally provided by the healthcare system's endoscopy department.
The investigators hypothesize the following: (1) participants who receive the tailored DVD plus the patient navigation intervention will have higher rates of CRC screening with the fecal immunochemical test (FIT), colonoscopy, or either screening test compared to those who receive the tailored DVD alone; (2) participants who receive either intervention (DVD only or DVD plus patient navigation) will have higher rates of CRC screening with FIT, colonoscopy, or either screening test than those who receive usual care; and (3) participants who receive either intervention who complete colonoscopy will have better quality of bowel preparation, less anxiety about the procedure, and greater satisfaction with the colonoscopy experience than those who receive usual care.
Tutkimuksen yleiskatsaus
Tila
Ehdot
Interventio / Hoito
Yksityiskohtainen kuvaus
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Indiana
-
Indianapolis, Indiana, Yhdysvallat, 46202
- Eskenazi Health
-
Indianapolis, Indiana, Yhdysvallat, 46202
- Indiana University School of Nursing
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Referred for a screening colonoscopy that was not done (i.e, canceled or no show)
Exclusion Criteria:
- Unable to speak, read, and write English
- Personal history of CRC or polyps
- Personal history of conditions that place participants at high risk for CRC such as ulcerative colitis, Crohn's disease, or known hereditary syndromes such as familial adenomatous polyposis or hereditary nonpolyposis colorectal cancer
- Family history of CRC which increases the participant's risk for CRC
- Advised by a health care provider to not have a colonoscopy due to the participant's health
- Speech impairment
- Hearing impairment
- Cognitive impairment
- Vision impairment
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Seulonta
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Active Comparator: Tailored DVD
Tailored digital video disc (DVD)
|
A 20 minute tailored DVD titled "Approaches to Colon Testing" is viewed by participants.
It is designed to encourage CRC screening uptake by colonoscopy or FIT by increasing the participant's CRC knowledge and beliefs about the benefits of screening, reducing barriers to screening, and increasing self-efficacy for screening by demonstrating how these tests are performed.
|
|
Active Comparator: Tailored DVD + Patient Navigation
Tailored digital video disc (DVD) plus Patient Navigation by a population health nurse in the healthcare system
|
A 20 minute tailored DVD titled "Approaches to Colon Testing" is viewed by participants.
It is designed to encourage CRC screening uptake by colonoscopy or FIT by increasing the participant's CRC knowledge and beliefs about the benefits of screening, reducing barriers to screening, and increasing self-efficacy for screening by demonstrating how these tests are performed.
Participants talk by telephone with a Patient Navigator who is a trained nurse.
The Patient Navigator determines if participants viewed the tailored DVD and answers any questions about the content.
The Patient Navigator then provides telephone counseling on CRC and screening tests to: (1) increase knowledge, perceived benefits, and self-efficacy; (2) reduce barriers; (3) enhance access; and (4) provide social support.
|
|
Ei väliintuloa: Usual Care
Care normally provided by a nurse in the endoscopy department of the healthcare system
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Participants Completing CRC Screening Per Electronic Medical Record Documentation
Aikaikkuna: 12 months post-baseline interview
|
Number of participants completing CRC screening by any test (defined as colonoscopy or FIT) is measured by electronic medical record review.
Dates that participants had a colonoscopy and dates of FIT analysis are extracted from the electronic medical record.
|
12 months post-baseline interview
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Participants Completing Colonoscopy Per Electronic Medical Record Documentation
Aikaikkuna: 12 months post-baseline interview
|
Number of participants completing a colonoscopy is measured by electronic medical record review (EMR).
Dates that participants completed a colonoscopy are extracted from the EMR.
|
12 months post-baseline interview
|
|
Bowel Preparation Quality Rating Using Boston Bowel Preparation Scale
Aikaikkuna: 12 months post-baseline interview
|
Participants quality of bowel preparation is measured by the endoscopist during their colonoscopy procedure using the Boston Bowel Preparation Scale (BBPS).
BBPS scores the total quality on a 10 point scale from 0-9.
Higher scores indicate better quality of bowel preparation.
|
12 months post-baseline interview
|
|
Participants With Adequate Quality of Bowel Preparation Per Modified Aronchick Rating Scale
Aikaikkuna: 12 months post-baseline interview
|
Participants quality of bowel preparation is measured by the endoscopist during their colonoscopy using a modification of the Aronchick rating scale.
The Aronchick scale rates quality as 1=excellent, 2=good, 3=fair, or 4=poor.
Some endoscopists choose to grade quality more generally as adequate vs. inadequate.
To accommodate this variation, bowel preparation ratings have been dichotomized into adequate (excellent, good, fair, or adequate ratings) vs. inadequate (poor or inadequate ratings).
Adequate is scored as 1 and indicates better quality of bowel preparation than inadequate which is scored as 0.
|
12 months post-baseline interview
|
|
Colonoscopy-Related Procedural Anxiety for Participants Completing a Colonoscopy
Aikaikkuna: 12 months post-baseline interview
|
Colonoscopy-related procedural anxiety is measured by self-report using the 6-item short form of the State Anxiety Scale of the State-Trait Anxiety Inventory.
Each item is scored from 1 to 4 (1=not at all; 4=very much so) with higher scores indicating greater anxiety.
|
12 months post-baseline interview
|
|
Satisfaction With Colonoscopy Experience
Aikaikkuna: 12 months post-baseline interview
|
Satisfaction with the colonoscopy experience is measured by self-report using a single item developed by the research team.
Satisfaction is rated from 1 to 4 where 1=not at all satisfied, 2=a little satisfied, 3=mostly satisfied, and 4=completely satisfied.
Scores range from 1 to 4 with higher scores indicating greater satisfaction.
|
12 months post-baseline interview
|
|
Participants Completing a Fecal Immunochemical Test (FIT) Per Electronic Medical Record Documentation
Aikaikkuna: 12 months post-baseline interview
|
Number of participants completing a FIT is measured by electronic medical record review (EMR).
Dates of FIT analysis are extracted from the EMR.
|
12 months post-baseline interview
|
|
Participants Who Self-Reported Completing CRC Screening
Aikaikkuna: 6-9 months post-baseline interview
|
Number of participants who reported completing CRC screening by any test (defined as colonoscopy or FIT) during the 6 or 9 month post-baseline telephone interview.
|
6-9 months post-baseline interview
|
|
Participants Who Self-Reported Completing a Colonoscopy
Aikaikkuna: 6-9 months post-baseline interview
|
Number of participants who reported completing a colonoscopy during the 6 or 9 month post-baseline telephone interview.
|
6-9 months post-baseline interview
|
|
Participants Who Self-Reported Completing a Fecal Immunochemical Test (FIT)
Aikaikkuna: 6-9 months post-baseline interview
|
Number of participants who reported completing a FIT during the 6 or 9 month post-baseline telephone interview.
|
6-9 months post-baseline interview
|
|
Change in Knowledge of CRC and Screening
Aikaikkuna: 6 months post-baseline interview
|
Change from baseline in knowledge of CRC and screening is measured at 6 months by self-report using a 9-item multidimensional scale.
Each item is scored as 1=correct or 0=incorrect and summed to yield a scale score.
Scores range from 0 to 9 with higher summated scores indicating greater knowledge of CRC and screening tests.
The mean of the 9 items is calculated at baseline and 6 months post-baseline.
Change from baseline equals the mean at 6 months minus the mean at baseline.
Change can range from -9 to 9 with positive values indicating an increase in knowledge.
|
6 months post-baseline interview
|
|
Change in Perceived Risk for CRC
Aikaikkuna: 6 months post-baseline interview
|
Change from baseline in perceived risk for CRC is measured by self-report at 6 months using a 3-item scale.
We ask participants how likely it is that they will get colon cancer sometime during their lifetime, within the next 10 years, and within the next 5 years.
Each item is scored from 1 to 4 (1=very unlikely; 4=very likely).
Higher scores indicate a higher perceived risk for getting CRC.
The mean of the 3 items is calculated at baseline and 6 months.
Change in perceived risk equals the mean at 6 months minus the mean at baseline.
Change can range from -3 to 3 with positive values indicating an increase in perceived risk for getting CRC.
|
6 months post-baseline interview
|
|
Change in Colonoscopy-Related Procedural Anxiety Regardless of Whether or Not Participants Had a Colonoscopy
Aikaikkuna: 6 months post-baseline interview
|
Change from baseline in colonoscopy-related procedural anxiety is measured at 6 months by self-report using the 6-item short form of the State Anxiety Scale of the State-Trait Anxiety Inventory.
Each item is scored from 1 to 4 (1=not at all; 4=very much so) with higher scores indicating greater anxiety.
The mean of the 6 items is calculated at baseline and 6 months post-baseline.
Change from baseline is the mean at 6 months minus the mean at baseline.
Change can range from -3 to 3 with positive values indicating an increase in anxiety.
|
6 months post-baseline interview
|
|
Change in Perceived Benefits of CRC Screening by Colonoscopy
Aikaikkuna: 6 months post-baseline interview
|
Change from baseline in perceived benefits of CRC screening by colonoscopy is measured at 6 months by self-report using a 4-item scale.
Each item is scored from 1 to 4 (1=strongly disagree; 4=strongly agree) and the mean of the 4 items calculated.
Higher mean scores indicate greater perceived benefits of screening by colonoscopy.
Change in perceived benefits equals the mean at 6 months minus the mean at baseline.
Change can range from -3 to 3 with positive values indicating an increase in perceived benefits of screening by colonoscopy.
|
6 months post-baseline interview
|
|
Change in Perceived Barriers to CRC Screening by Colonoscopy
Aikaikkuna: 6 months post-baseline interview
|
Change from baseline in perceived barriers to CRC screening by colonoscopy is measured at 6 months by self-report using a 16-item scale.
Each item is scored from 1 to 4 (1=strongly disagree; 4=strongly agree) and the mean of the 16 items calculated.
Higher mean scores indicate greater perceived barriers to screening by colonoscopy.
Change in perceived barriers equals the mean at 6 months minus the mean at baseline.
Change can range from -3 to 3 with negative values indicating a decrease in perceived barriers to screening by colonoscopy.
|
6 months post-baseline interview
|
|
Change in Perceived Self-Efficacy for CRC Screening by Colonoscopy
Aikaikkuna: 6 months post-baseline interview
|
Change from baseline in perceived self-efficacy for colonoscopy is measured at 6 months by self-report using an 11-item scale.
Each item is scored from 1 to 4 (1=not at all sure; 4=very sure) and the mean of the 11 items calculated.
Higher mean scores indicate greater perceived self-efficacy for screening by colonoscopy.
Change in perceived self-efficacy equals the mean at 6 months minus the mean at baseline.
Change can range from -3 to 3 with positive values indicating an increase in perceived self-efficacy for screening by colonoscopy.
|
6 months post-baseline interview
|
|
Change in Perceived Benefits of CRC Screening by FIT
Aikaikkuna: 6 months post-baseline interview
|
Change from baseline in perceived benefits of CRC screening by FIT is measured at 6 months by self-report using a 3-item scale.
Each item is scored from 1 to 4 (1=strongly disagree; 4=strongly agree) and the mean of the 3 items calculated.
Higher mean scores indicate greater perceived benefits of screening by FIT.
Change in perceived benefits equals the mean at 6 months minus the mean at baseline.
Change can range from -3 to 3 with positive values indicating an increase in perceived benefits for screening by FIT.
|
6 months post-baseline interview
|
|
Change in Perceived Barriers to CRC Screening by FIT
Aikaikkuna: 6 months post-baseline interview
|
Change from baseline in perceived barriers to CRC screening by FIT is measured at 6 months by self-report using a 10-item scale.
Each item is scored from 1 to 4 (1=strongly disagree; 4=strongly agree) and the mean of the 10 items calculated.
Higher mean scores indicate greater perceived barriers to screening by FIT.
Change in perceived barriers equals the mean at 6 months minus the mean at baseline.
Change can range from -3 to 3 with negative values indicating a decrease in perceived barriers to screening by FIT.
|
6 months post-baseline interview
|
|
Change in Perceived Self-Efficacy for CRC Screening by FIT
Aikaikkuna: 6 months post-baseline interview
|
Change from baseline in perceived self-efficacy for CRC screening by FIT is measured at 6 months by self-report using a 7-item scale.
Each item is scored from 1 to 4 (1=not at all sure; 4=very sure) and the mean of the 7 items calculated.
Higher mean scores indicate greater perceived self-efficacy for screening by FIT.
Change in perceived self-efficacy equals the mean at 6 months minus the mean at baseline.
Change can range from -3 to 3 with positive values indicating an increase in perceived self-efficacy for screening by FIT.
|
6 months post-baseline interview
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Päätutkija: Susan M Rawl, PhD,RN, Indiana University
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- 1605880142
- IHS-1507-31333 (Muu apuraha/rahoitusnumero: Patient-Centered Outcomes Research Institute (PCORI))
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
IPD-jaon aikakehys
IPD-jaon käyttöoikeuskriteerit
IPD-jakamista tukeva tietotyyppi
- STUDY_PROTOCOL
- MAHLA
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Peräsuolen syöpä
-
National Cancer Institute (NCI)RekrytointiStage III Sinonasal Cancer AJCC v8 | Stage IVA Sinonasal Cancer AJCC v8 | Vaihe IVB Sinonasal Cancer AJCC v8 | Sinonasaalinen okasolusyöpäYhdysvallat
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)ValmisLymfaödeema | Perioperatiiviset/postoperatiiviset komplikaatiot | Vaiheen II Vulvar Cancer AJCC v7 | Vaihe IIIA Vulvar Cancer AJCC v7 | Vaihe IIIB Vulvar Cancer AJCC v7 | Vaihe IIIC Vulvar Cancer AJCC v7 | Stage IVA Vulvar Cancer AJCC v7 | Vaihe IA Vulvar Cancer AJCC v7 | Vaihe IB Vulvar Cancer AJCC v7 | Vaihe...Yhdysvallat
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Aktiivinen, ei rekrytointiVaiheen III vulvar Cancer AJCC v7 | Vaihe IIIA Vulvar Cancer AJCC v7 | Vaihe IIIB Vulvar Cancer AJCC v7 | Vaihe IIIC Vulvar Cancer AJCC v7 | Epäsuoran levyepiteelisyöpä | Stage IVA Vulvar Cancer AJCC v7Yhdysvallat
-
Samsung Medical CenterValmisHER2-positiivinen Refractory Advanced CancerKorean tasavalta
-
Everest Medicines (Beijing) Co., Ltd.Ei vielä rekrytointiaSquamous Non-Small Cell Lung Cancer sqNSCLC
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RekrytointiVaiheen II Vulvar Cancer AJCC v8 | Vaiheen IIIC vulvar Cancer AJCC v8 | Stage IVA Vulvar Cancer AJCC v8 | Kolmannen vaiheen ulkosynnyttäjäsyöpä AJCC v8 | Vaihe IIIA Vulvar Cancer AJCC v8 | Vaihe IIIB Vulvar Cancer AJCC v8Yhdysvallat
-
First Affiliated Hospital of Zhejiang UniversityYiwu Central HospitalEi vielä rekrytointiaMahalaukun adenokarsinooma | Esophagogastric Juction Cancer | Asiantunteva yhteensopivuusvirheiden korjausKiina
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityAktiivinen, ei rekrytointiHaiman adenokarsinooma | Stage III haimasyöpä American Joint Committee on Cancer v8 | T0-tasainen haimasyöpä American Joint Committee on Cancer v8 | Vaiheen I haimasyöpä American Joint Committee on Cancer v8 | Vaiheen IV haimasyöpä American Joint Committee on Cancer v8Yhdysvallat
-
Massachusetts General HospitalValmisColoRectal syövän seulonta
-
University of UtahNational Cancer Institute (NCI)ValmisVäsymys | Istuva elämäntapa | Metastaattinen eturauhassyöpä | Stage IV Prostate Cancer AJCC (American Joint Committee on Cancer) v8 | Stage IVA Eturauhassyöpä AJCC (American Joint Committee on Cancer) v8 | Stage IVB Eturauhassyöpä AJCC (American Joint Committee on Cancer) v8Yhdysvallat
Kliiniset tutkimukset Tailored DVD
-
The Miriam HospitalNational Institute of Mental Health (NIMH); Brown University; University of... ja muut yhteistyökumppanitValmisHIV-infektiot | Sukupuolitaudit | HIVYhdysvallat
-
AmgenValmis
-
The University of Hong KongThe Boys' and Girls' Clubs Association of Hong KongValmis
-
VA Office of Research and DevelopmentValmis
-
Case Comprehensive Cancer CenterAmerican Cancer Society, Inc.; Consumer Wellness Solutions; North Carolina...ValmisTupakan käytön lopettaminenYhdysvallat
-
Stanford UniversityLucile Packard Children's HospitalValmis
-
University of Texas Southwestern Medical CenterAgency for Healthcare Research and Quality (AHRQ)ValmisRintojen kasvaimet | Keuhkojen kasvaimet | Paksusuolen kasvaimetYhdysvallat
-
IRCSS Istituto Dermopatico dell'Immacolata, Fondazione...Ministry of Health, Italy; Centro di Eccellenza per la Cultura e la Ricerca...Valmis
-
University of RochesterThe Commonwealth Fund; Academic Pediatric AssociationValmis
-
Washington University School of MedicineValmis